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THERAPY AND PREVENTION-ANGINA PECTORIS
Although they are all effective in treating myocardial ischemia, the calcium-channel blockers most studied -diltiazem, nifedipine, and verapamil -differ in their hemodynamic and electrophysiologic actions and in their side effect profiles." 12 Because drugs of this class continue to be used, it is essential that comparative data be obtained and made available to clinicians so that informed decisions regarding the optimum agent to be used under specific circumstances can be made. There have been studies comparing verapamil with nifedipine in patients with effort angina,13-15 but a paucity of information is available on the comparison of diltiazem and nifedipine .16 This study was designed to identify differences, if any, in the antianginal effectiveness and safety of diltiazem vs nifedipine as monotherapies in patients with chronic stable angina. Since these two calcium-channel blockers have different pharmacologic properties, the study was also designed to evaluate the possible beneficial effects of the combination of nifedipine and diltiazem in patients who remain symptomatic despite maximum doses of either drug alone. The effects of treatment on the ambulatory electrocardiogram were also assessed.
Methods
Subjects. The study group consisted of 24 ambulatory patients (19 men Patients who had a myocardial infarction or who had undergone cardiac surgery within 3 months were excluded. Patients with the following characteristics were also excluded: congestive heart failure; moderate-severe hypertension; systolic blood pressure less than 90 mm Hg; electrocardiographic (ECG) evidence of left bundle branch block or left ventricular hypertrophy; severe bradycardia (<50 beats/min at rest); atrioventricular block; sick sinus syndrome; significant valvular or congenital heart lesions; need for concomitant therapy with antiarrhythmic agents (including digitalis); evidence of anemia, diabetes mellitus requiring insulin, renal failure, hepatic failure; history of asthma, emphysema, or peripheral vascular disease; and a past hypersensitivity to calcium entry-blocking drugs. Patients unresponsive to sublingual nitroglycerin and those unable to undergo repeated exercise testing were also excluded. Study design. During the study, patients were permitted sublingual nitroglycerin (0.6 mg) as the only antianginal medication other than the study medications. Nitroglycerin tablets were to be used as needed by patients to treat angina, but not prophylactically. Therapy with digitalis, 0-adrenergic blockers long-acting nitrates, and antiarrhythmic drugs was withdrawn at least 1 week before study entry.
The study protocol (figure 1) consisted of a qualification phase, during which time patients were considered for study inclusion by use of criteria previously described. This was followed by an initial 2 week, single-blind, placebo washout phase in which all previous antianginal therapies except sublingual nitroglycerin were discontinued. Patients received two placebo tablets (identical in appearance to subsequent medications) three times daily. Patientswere required to have two consecutive stress tests with exercise times within 2 min of each other, and each patient had to have at least five episodes of angina per week during the placebo run-in phase. Patients who fulfilled these criteria were randomized and entered the double-blind crossover drug treatment phase. Randomization during the initial doubleblind crossover phase was maintained by having the sponsor code and prepackage the capsules before shipment to the investigators. The double-blind crossover phase consisted of two 3 week treatment periods separated by a 1 to 2 week placebo washout. The first 2 weeks of each treatment period was also a dose-titration period during which doses of medications were increased every 1 to 2 days from one capsule (capsule contained either 30 mg of diltiazem or 10 mg of nifedipine), up to four capsules every 8 hr. Thus, the maximum allowable doses of nifedipine and diltiazem were 120 and 360 mg/day, respectively. Titration was limited when the maximum allowed dose was reached or when intolerable adverse experiences occurred. Patients were evaluated at their maximum tolerated doses. The dosage attained during the titration period was maintained for the remainder of the double-blind treatment period. Doses of placebo for the washout periods after each of the double-blind treatment periods was two capsules three times daily. There was no down-titration of active medication before the placebo washout periods. The placebo washout period lasted 1 week unless the patient had experienced fewer than five attacks of angina by the end of the week. In this case, the placebo period was extended an additional week. Patients who were asymptomatic during one or both double-blind monotherapy periods completed the study after the second active treatment washout.
Those patients who remained symptomatic during both double-blind periods participated in the combination phase. This phase consisted of a 3 week period of combined diltiazem and nifedipine treatment. On completion of the second double-blind treatment period, each patient's medication schedule was unblinded to determine the doses to be used in the combination phase. Each patient received first the drug that was most clinically effective in the maximum dose achieved and tolerated. The other calcium blocker was then administered, as during the double-blind phase, in a close titration study to achieve maximum therapeutic effects. The decision as to which drug was the most clinically effective was made before unblinding and was made jointly by the investigator and a representative of the sponsor's monitoring team. The decision was based on exercise tolerance variables, frequency of angina, and nitroglycerin consumption.
After the combination phase, all remaining patients underwent a final 1 week washout period.
Methods of observation. All patients kept a detailed daily record of their angina and sublingual nitroglycerin consumption needed to abort attacks. Patients were given a new diary at each visit to be completed and returned at the following visit. From this record, weekly episodes of angina, nitroglycerin consumption, and angina-free days were calculated. Every week patients were evaluated with a detailed history and cardiopulmonary examination that included measurements of supine and standing (3 min) heart rate and blood pressure. Blood pressure and heart rate determinations were made at the same time of day for each patient: 2 to 5 hr after ingestion of medication, when peak blood drug levels are usually seen. Patients also underwent stress testing at the onset and conclusion of the initial placebo period, at the end of the second and third weeks of the double-blind treatment periods, at the end of the posttreatment placebo periods, and at the second and third weeks of the combination phase. Ambulatory 24 hr ECG monitoring examinations to assess ST segment deviations were performed at the end of the run-in placebo phases, during the last week of the active treatment phases (including combination), and at the end of each treatment withdrawal period.
At the end of the initial placebo treatment phase, the active treatment phases, and treatment withdrawal phases, blood specimens were obtained for complete blood count, platelet counts, and biochemical screening (total protein, albumin, calcium, phosphate, cholesterol, triglycerides, uric acid, urea nitrogen, glucose, sodium, potassium, creatinine, carbon dioxide, chloride, total bilirubin, alkaline phosphatase, SGPT, lactic dehydrogenase, SGOT, and creatine kinase). Chest roentgenograms, routine urinalysis, and resting electrocardiograms were performed. Two tubes of blood for determination of plasma nifedipine and diltiazem levels were obtained at the end of the placebo run-in, weekly during each treatment period, and once during the treatment washout period.
Data on adverse experiences were compiled from patient self-reporting (without a questionnaire) and from direct observations of the investigator. Adverse An interval of at least 2 min without ST segment deviation was required after the resolution of each episode before another discrete ischemic episode was counted. The technician identified any potential ischemic episode as defined above, noting the onset and duration, and provided a recording on paper of each episode. In addition, hourly examples of baseline measurements without ST changes were recorded on paper. The findings were then reviewed by three independent investigators who reviewed the findings blindly and independently. Arrhythmias were also monitored and recorded in the study.
Plasma drug levels. Two coded samples of blood for diltiazem and nifedipine plasma levels were obtained every week of the study. Nifedipine plasma levels were measured by gas chromatography (Biodecision Labs, Pittsburgh)'8; diltiazem plasma levels were measured by a reverse high-pressure liquid chromatography method with the use of organic extraction with ultraviolet detection (Marion Labs., Kansas City, MO). '9 Statistical method. All comparisons were made with data from patients on the highest doses achieved at the end point of therapy and data from the end points of placebo therapy. Mean data are presented with + SD as the index of dispersion. In the tables, + SEM is used as the index of dispersion.
Patients were randomly assigned to treatment sequences after a two period crossover design. Paired t tests were used to compare each active treatment to the initial placebo run-in (baseline). To compare diltiazem and nifedipine, the changes from baseline were analyzed by Koch's nonparametric twoperiod crossover analysis. Active monotherapy was compared with combination therapy by two-way analysis of variance performed on the changes from baseline, followed by preplanned contrasts. The number of patients reporting adverse reactions was determined and the active treatments were compared by the TABLE 1 Effects of placebo, diltiazem, and nifedipine on frequency of angina attacks, nitroglycerin (NTG) consumption, exercise tolerance, resting and exercise heart rate, blood pressure (BP), and double product, and episodes of spontaneous ST segment depressions on the ambulatory 24 Effects of monotherapy on angina pectoris and nitroglycerin consumption (figure 2, tables 1 and 3). Both diltiazem and nifedipine were effective in reducing anginal attacks and nitroglycerin consumption and increasing angina-free days compared with placebo; diltiazem was more effective than nifedipine in relieving angina. Three patients receiving nifedipine developed an increase in attacks of angina compared with placebo; they had not had angina on placebo.
With withdrawal of medications, only one patient developed a severe exacerbation of angina (after nifedipine withdrawal); this patient continued in the study. Overall, patients returned to baseline angina levels without evidence of an "overshoot" in symptoms compared with placebo baseline.
Effects of monotherapy on resting and exercise blood pressure and heart rate. Compared with placebo, both drugs reduced supine and standing systolic and diastolic blood pressures at rest. Nifedipine had a greater effect than diltiazem with respect to reducing standing systolic blood pressure. Heart rate was reduced with diltiazem in both the supine and standing positions when compared with heart rate on placebo and nifedipine. Both drugs reduced the standing rate-pressure product at rest; this effect was greater with nifedipine.
At peak exercise (end point pain or fatigue) there were no differences observed in blood pressure and rate-pressure product variables with either drug compared with placebo. Peak heart rate was higher with nifedipine than diltiazem.
With withdrawal of each form of monotherapy, there was a return to baseline rest and exercise heart rate and blood pressure variables.
Effects of monotherapy on exercise tolerance (tables 1 and 2, figure 3 ). Compared with placebo, both nifedipine and diltiazem increased exercise duration, exercise work, the time to 1 mm ECG ST segment depression, and the 780 time to pain onset. There were no differences between the two drugs. a greater reduction in standing diastolic blood pressure, rest rate-pressure product, and peak exercise heart rates. Compared with diltiazem, combination therapy improved total exercise work performed and time to pain onset. The combination caused a greater reduction in standing systolic and diastolic blood pressure at rest and in peak exercise diastolic pressure. The benefit seen on the ambulatory electrocardiogram with diltiazem monotherapy was lost with combination therapy. There was no effect of combination therapy on the number of ST segment deviations: 9.6 ± 4.7 episodes/24 hr on placebo before the combination and MEAN HEART RATE FIGURE 4. Episodes of ST segment depression (left) and heart rates (right) during concurrent 24 hr periods. Diltiazem reduced episodes of ST segment depression, whereas nifedipine had no effect. During the 24 hr monitoring periods, diltiazem caused a greater reduction in heart rate than did nifedipine. Data are given as the mean + SEM.
8.8 + 8.8 episodes/24 hr on combination treatment. This lack of change occurred despite improvement in angina with combination treatment. There was no evidence of a withdrawal reaction when combination therapywas discontinued when compared with the reaction to withdrawal of precombination placebo and baseline placebo.
Adverse effects (table 4) . Significantly more adverse reactions were observed with nifedipine than with placebo or diltiazem. The most frequently observed side effect was dizziness, which was more commonly reported with nifedipine. Patients receiving combination therapy suffered more side effects than those on either nifedipine or diltiazem monotherapy.
One patient assigned to diltiazem therapy alone was excluded because of a nonfatal myocardial infarction that was not preceded by unstable angina. Early in the combination treatment phase, four patients were excluded because of intolerable dizziness and palpitations. Four patients developed worsening of their angina compared with that on placebo (three on nifedipine, one on combination therapy), but did not drop out of the study. Three patients developed near syncope (a feeling suggestive of an oncoming fainting spell; one each on diltiazem, nifedipine, and combination therapy). One patient developed asymptomatic Mobitz type I heart block on diltiazem.
There was no increase in body weight observed with active treatment and there were no effects of therapy on serum triglycerides and cholesterol.
Discussion
The therapeutic efficacy ofcalcium-channel blockers in patients with stable effort angina has been well established. 16 and none in which the drugs were used in combination.
In this double-blind study, in which high therapeutic doses of diltiazem27 and nifedipine were used, both drugs were more effective than placebo in reducing angina. However, diltiazem was the more effective antianginal agent. This difference between the drugs may relate to their hemodynamic actions: Diltiazem causes a lowering of heart rate and has a greater effect with respect to reducing "sympathetic tone" than nifedipine. A similar observation was made with verapamil, a rate-lowering calcium blocker that was found to be more effective in treating angina pectoris than nifedipine.14 All patients in our study obtained relief of their anginal symptoms with diltiazem, whereas three patients receiving nifedipine experienced a worsening of their symptoms compared with baseline.14 Other investigators have reported similar findings with nifedipine in patients with angina,28-31 and again, this may relate to the reflex increase in heart rate and myocardial contractility caused by the drug. It is often recommended that nifedipine be combined with 13-adrenergic blockers to avoid tachycardia.32 The problem of tachycardia with nifedipine may dissipate when slow-release preparations of nifedipine become available.
Both nifedipine and diltiazem were shown to cause a marked improvement in treadmill exercise tolerance in this study, while allowing patients to achieve the same rate-pressure product at peak exercise observed at placebo baseline. This contrasts sharply with the findings when 1-blockers were used in patients with angina who could not achieve the same rate-pressure product achieved off therapy.33
In this study, the effects of diltiazem and nifedipine on the ambulatory electrocardiogram were assessed. Identification of episodes of myocardial ischemia that are painless or silent is generally based on detection of ST segment deviations recorded by ambulatory electrocardiography, with special units designed to assess the ST segment during activities of everyday life.34 35 The use of the ambulatory electrocardiogram provides quantifiable criteria for assessment of anti-ischemic interventions, as well as providing objective assessment of the subjective event of anginal pain. Painless CIRCULATION difference may relate again to the effects of the two drugs on heart rate. The episodes of ischemia with nifedipine were observed at a higher heart rate than the episodes that occurred over most of the day with drug treatment. Our observations comparing the rate-lowering calcium-blocker diltiazem to nifedipine were similar to those reported when verapamil was compared with nifedipine.14 In that study, only verapamil was effective in reducing episodes of ST segment depression on the ambulatory electrocardiogram. '4 These investigators suggested that the different heart rate effects of verapamil and nifedipine were the contributing factors.14 There are studies, however, using lower doses of nifedipine, that reported reductions in episodes of ST depression on the ambulatory electrocardiogram with the drug. 21 Many of the differences observed between diltiazem and nifedipine in this study may relate to the pharmacologic differences between the calcium entryblocking drugs." 9, 12, 40 Unlike the 3-adrenoceptorblocking drugs, which have a common pharmacologic action and are essentially interchangeable in patients with angina pectoris,41 this is not the situation with the calcium blockers. Although these drugs all inhibit the transmembrane flux of calcium ions into cells, they appear to have different binding sites on the cell membrane, different hemodynamic and electrophysiologic effects, different effects on regional circulations, and varied adverse effect profiles.12 It was these differences between drugs that suggested the possibility that combination diltiazem/nifedipine therapy might be more efficacious than monotherapy after maximum doses failed to achieve desired clinical outcomes.
In this study, combination diltiazem/nifedipine therapy was more effective in patients who could tolerate the regimen, than monotherapy in patients not responding maximally to diltiazem or nifedipine. Combination therapy was more effective than nifedipine alone in reducing angina attacks and improving exercise tolerance, and more effective than diltiazem alone on some variables of exercise tolerance. One patient did develop increased anginal symptoms on combination treatment, and there were no effects of combination treatment on the number of ST segment deviations on the ambulatory electrocardiogram. There were greater effects of combination treatment on resting blood pressure than with monotherapy.
Withdrawal reactions (unstable angina, myocardial infarction) have been described after discontinuation of long-term ,-blocker therapy in patients with chronic stable angina.42 The mechanism for this may relate to hypersensitive adrenergic receptors that develop during 784 t-blocker therapy, which are then exposed to catecholamine stimulation after withdrawal of the drug. 42 Our group could not demonstrate any such withdrawal reaction when verapamil therapy was discontinued in patients with angina, 43 and were unable to demonstrate such reactions in this study in patients withdrawing from diltiazem, nifedipine, or combination therapy.
There was a return to pretreatment levels of blood pressure, heart rate, and frequency of angina attacks in the patients. Exercise variables returned toward, but not to, placebo treatment values, as one would expect in a study in which so many serial stress tests are being done. However, the effects of active therapy on exercise variables in our study were demonstrated despite the "training effect."
Plasma drug levels have been used to monitor certain antiarrhythmic drug actions and to prevent toxicity. Similar to our findings previously described with propranolol,33 labetalol,44 and verapamil45 in patients with angina, both diltiazem and nifedipine plasma levels showed a wide interindividual difference and were not useful for predicting a clinical outcome (effects on angina, exercise tolerance) in any particular patient. However, the plasma levels did help to monitor patient compliance with medication regimens in the study, and in clinical practice, plasma diltiazem and nifedipine levels could be used for this purpose and to help assess patients who overdose.
Regarding drug plasma levels, an interesting observation was made during combination diltiazem-nifedipine treatment in this study. On combination treatment, plasma levels of nifedipine were higher than those during nifedipine monotherapy in which twice the dose was used. This was not observed with diltiazem in combination. Since both diltiazem and nifedipine are metabolized in the liver, perhaps diltiazem interferes with metabolism of nifedipine. The validity of this observation needs to be confirmed in future studies.
Calcium-entry blockers are well tolerated in most patients with angina pectoris who have no major contraindications to this form of therapy. In this study in which high therapeutic doses were used, there were more adverse reactions observed with active therapy than with placebo. Nifedipine was associated with more than twice the adverse reactions associated with diltiazem. Dizziness was significantly more common with nifedipine and aggravation of angina was described in three patients on this drug. One patient on diltiazem did develop an acute myocardial infarction. Combination therapy was associated with even more adverse reactions than either nifedipine or diltiazem CIRCULATION alone, with four patients having to terminate this therapy prematurely because of intolerable dizziness and palpitations. This increase in adverse reactions with combination therapy may relate to an additive vasodilator effect with both drugs or a potentiation of nifedipine's clinical effects by diltiazem. In the future, smaller doses of nifedipine should be used in combination with diltiazem to allow for optimal use of this combination.
Whenever one active drug is compared with another, it is never known whether comparable antianginal doses are being used and this is always a limitation of this type of study. However, with the dosing regimens described in this study, diltiazem as a single agent is more effective than nifedipine in relieving painful and painless ischemic episodes, while having a more favorable side effect profile. Both drugs are effective in improving exercise tolerance. Combination nifedipine/ diltiazem therapy is an alternative in patients not responding to monotherapy; however, the intolerable side effect profile accompanying this regimen prohibits recommendation of this regimen as a routine approach. There is no evidence of a dangerous diltiazem/nifedipine withdrawal reaction. A pharmacologic interaction may occur when diltiazem is combined with nifedipine, with an increase in plasma levels of nifedipine.
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